Drug screening for Pelizaeus-Merzbacher disease by quantifying the total levels and membrane localization of PLP1.

ABSTRACT:

Background

Pelizaeus-Merzbacher disease (PMD) is caused by point mutations or copy number changes in the proteolipid protein 1 gene (PLP1). PLP1 is exclusively localized in the myelin sheath of oligodendrocytes. Amino acid-substituted PLP1 protein is unable to fold properly and is subsequently degraded and/or restrictedly translated, resulting in a decrease in the PLP1 protein level and a failure to localize to the membrane. Furthermore, misfolded proteins increase the burden on the intracellular quality control system and trafficking, finally resulting in cell apoptosis. The objective of this study was to identify therapeutic chemicals for PMD by quantifying the total levels and membrane localization of PLP1.

Method

We established a cell line stably expressing

SUBMITTER: Kouga T 

PROVIDER: S-EPMC6510973 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature